Wall St. slips on healthcare, consumer names; Fed eyed

Nomura Securities Raises Price Target on Tiffany & Co. (TIF) Following Better-Than-Expected 2Q

Nomura Securities reiterated a Buy rating on Tiffany & Co. (NYSE: TIF), and raised the price target to $76.00 (from $64.00), following the company's 2Q earnings report. TIF posted meaningfully better-than-expected GMs in 2Q for a third straight quarter of >200bp expansion. The beat allowed management... More

Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand

Mylan N.V. (Nasdaq: MYL) announced that its U.S. subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC"), of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton... More

Jefferies Cuts Price Target on Dollar General (DG) to $78 Following 2Q Report

Jefferies maintained a Hold rating on Dollar General (NYSE: DG), and cut the price target to $78.00 (from $96.00), following the company's 2Q earnings report. Same store sales increased 0.7%, short of the Street's expectation for +2.7%. EPS of $1.08 was a penny short of Street expectation.

Analyst... More

UBS Cuts Price Target on Dollar Tree (DLTR) to $100; Reiterates Buy

UBS maintained a Buy rating on Dollar Tree (NASDAQ: DLTR), and cut the price target to $100.00 (from $108.00), following the company's 2Q earnings report.

Analyst Michael Lasser commented, "Its easy to take the view that WMT is becoming trouble for the dollar stores.... More

Piper Jaffray Remains Sidelined on Dollar Tree (DLTR) Following 2Q Comp Miss

Piper Jaffray maintained a Neutral rating on Dollar Tree (NASDAQ: DLTR), and cut the price target to $85.00 (from $87.00), following the company's 2Q earnings report. DLTR missed comps with 1.2% coming in below 2.5% estimates. Management noted cannibalization from the Deal$ and FDO store re-bannering to DLTR was a -80 bps headwind to comp.... More

UBS Cuts Price Target on Dollar General (DG) to $91; Reiterates Buy

UBS maintained a Buy rating on Dollar General (NYSE: DG), and cut the price target to $92.00 (from $101.00), following the company's 2Q earnings report.

Analyst Michael Lasser commented, "While it was convenient for the market to try and pin DGs slower SSS... More

EPS Beat Improves Cowen's Confidence on Tiffany & Co. (TIF); Reiterates Market Perform

Cowen reiterated a Market Perform rating on Tiffany & Co. (NYSE: TIF), and raised the price target to $74.00 (from $68.00), following the company's 2Q earnings report. TIF reported a worldwide comp decline of -9% C/C, partly attributed to lower tourist spending. However, a $0.12 EPS beat... More

Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore

Evercore ISI affirms Mylan (Nasdaq: MYL) with a Hold rating and $49 price target amid today's EpiPen cost-adjustment news.

The firm commented, Thanks to our top rated Specialty Pharma guru Umer Raffat (and CNBC) we are highlighting a slide Mylan is featuring (see below) in its... More